Balanites aegyptiaca Extract Inhibits COX-2 and P53 Expression in DSS-induced Ulcerative Colitis
Acta Scientifci Nutritional Health
Abbreviations Background: Histologically, the mouse model of DSS induced distal colitis resembles human colitis ulceration. The objective of this paper was to assess the potential protective role of Balanites aegyptiaca against DSS-induced colitis in rats model. Methods: Balanites aegyptiaca bioactive compounds was extracted and administered orally to DSS-induced colitic rats for 14 days. Results: Day after 14 days of oral treatment of Balanites aegyptiaca (100 and 200 mg/kg b.w.) and celecoxib
... (0.1 mmole/kg.b.w.) in rats, colon length and severity histological damages of the colon induced by DSS were reduced and the oxidisation status of the colon was improved. However, there is a significant decrease in the levels of various pro-inflammatory cytokines only in rats treated with balance-aegyptiaca and celecoxib; TNF-α, IFN-α, IL-1 and TBARS, along with a substantial increase to GSH and GST levels compared to DSS control groups. In addition, the expression of COX-2 and P53 proteins decreases significantly in the DSS control group compared to the Balanites aegyptiaca. Conclusion: The results clearly show that Balanites aegyptiaca exhibited anti-inflammatory properties in the DSS colitis model in rats that have also been enhanced by P53 and COX-2 protein expression functionalization. In the intestinal histoarchitecture Balanites aegyptiaca and Celecoxib almost normalised the effect of this effect compared to Celecoxib.